Efficacy

Polivy (polatuzumab vedotin-piiq) Efficacy in Treating Lymphoma

Polivy (polatuzumab vedotin-piiq) is a targeted cancer medicine that is used in combination with other drugs to treat certain types of non-Hodgkin lymphoma. Specifically, it is indicated for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), which is the most common type of non-Hodgkin lymphoma. The efficacy of Polivy was evaluated in a clinical study that included patients who had relapsed after or were refractory to at least two prior therapies. When used in combination with bendamustine and a rituximab product, Polivy has shown a significant improvement in overall response rate (ORR) and complete response rate (CRR) compared to treatments without Polivy.

In the pivotal trial that led to its approval, patients treated with the Polivy combination therapy demonstrated a higher complete response rate compared to those who received only bendamustine and rituximab. Furthermore, the median duration of response for patients who achieved a complete or partial response was significantly longer for those who received the Polivy combination. These results suggest that Polivy, when used as part of a combination regimen, can be an effective treatment option for patients with relapsed or refractory DLBCL.

Lunsumio (mosunetuzumab-axgb) Efficacy in Treating Lymphoma

Lunsumio (mosunetuzumab-axgb) is a bispecific antibody designed for the treatment of certain types of B-cell non-Hodgkin lymphoma. It targets two different proteins found on the surface of cells: CD20 on B cells and CD3 on T cells. By bringing these cells together, Lunsumio helps the body's immune system to attack and kill the cancerous B cells. The efficacy of Lunsumio has been evaluated in patients with relapsed or refractory follicular lymphoma, who have received at least two prior systemic therapies.

In clinical trials, Lunsumio has demonstrated promising efficacy in inducing responses in a significant proportion of patients with relapsed or refractory follicular lymphoma. The ORR and CRR were notably high, with many patients achieving a complete response. Additionally, the duration of response observed in these studies indicates that Lunsumio can provide a durable remission for some patients. These findings support the potential of Lunsumio as a new therapeutic option for patients with this challenging form of lymphoma, expanding the arsenal of treatments available to combat this disease.